Back to results
US 2020/0046694 A1Published application
Lanthionine synthetase c-like 2-based therapeutics
AssigneeLandos Biopharma, Inc.
InventorsJosep Bassaganya-Riera, Adria Carbo Barrios, Richard Gandour, Julian D. Cooper, Raquel Hontecillas
Life of this patent
Estimating the term…
Abstract
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.
Claims31
1-32. (canceled)
A compound of formula:
- or a pharmaceutically acceptable salt or ester thereof, wherein:
- Q is piperazine-1,4-diyl or substituted piperazine-1,4-diyl wherein the piperazine in the substituted piperazine-1,4-diyl is substituted with one to eight substituents in the 2, 3, 5, or 6 positions and wherein the substituents are independently selected from the group consisting of (C1 to C6)alkyl, aryl, aryl(C1 to C6)alkyl, C(O)OH, and C(O)O(C1 to C6)alkyl;
- A1 and A1′ are each independently N or CR6;
- A2 and A2′ are each independently N or CR7;
- A3 is NR8;
- A3′ is NR8, O, or S;
- A4 and A4′ are each independently N or CR9;
- A5 and A5′ are each independently N or CR10;
- A6 and A6′ are each independently N or CR11;
- and
- R1, R1′, R2, R2′, R3, R3′, R4, R4′, R6, R7, R8, R9, R10, and R11, if present, are in each instance independently selected from the group consisting of hydrogen, alkyl, halo, trifluoromethyl, dialkylamino wherein each alkyl is the same or different, —NH2, alkylamino, and arylalkyl.
8 more elements
A method of treating inflammatory bowel disease in an animal, the method comprising administering an effective amount of a compound to the animal, wherein the compound is a compound of formula:
- or a pharmaceutically acceptable salt or ester thereof, wherein:
- Q is piperazine-1,4-diyl or substituted piperazine-1,4-diyl wherein the piperazine in the substituted piperazine-1,4-diyl is substituted with one to eight substituents in the 2, 3, 5, or 6 positions and wherein the substituents are independently selected from the group consisting of (C1 to C6)alkyl, aryl, aryl(C1 to C6)alkyl, C(O)OH, and C(O)O(C1 to C6)alkyl;
- A1 and A1′ are each independently N or CR6;
- A2 and A2′ are each independently N or CR7;
- A3 is NR8;
- A3′ is NR8, O, or S;
- A4 and A4′ are each independently N or CR9;
- A5 and A5′ are each independently N or CR10;
- A6 and A6′ are each independently N or CR11;
- and
- R1, R1′, R2, R2′, R3, R3′, R4, R4′, R6, R7, R8, R9, R10, and R11, if present, are in each instance independently selected from the group consisting of hydrogen, alkyl, halo, trifluoromethyl, dialkylamino wherein each alkyl is the same or different, —NH2, alkylamino, and arylalkyl.
8 more elements
Dependencies are inferred from the claim text.